var data={"title":"Somatostatinoma: Clinical manifestations, diagnosis, and management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Somatostatinoma: Clinical manifestations, diagnosis, and management</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Emily Bergsland, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">David M Nathan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatinomas are rare neuroendocrine tumors of D-cell origin that contain and sometimes secrete excessive amounts of somatostatin (<a href=\"image.htm?imageKey=ENDO%2F80502\" class=\"graphic graphic_figure graphicRef80502 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"abstract_t\">1</a>]. This topic will review the clinical manifestations, diagnosis, and management of somatostatinomas. An overview of the clinical manifestations, diagnosis, and management of pancreatic neuroendocrine tumors is discussed in detail separately. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a> and <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;</a> and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">&quot;Insulinoma&quot;</a> and <a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">&quot;Glucagonoma and the glucagonoma syndrome&quot;</a> and <a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">&quot;Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)&quot;</a> and <a href=\"topic.htm?path=vipoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;VIPoma: Clinical manifestations, diagnosis, and management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1837026420\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatinomas are rare neuroendocrine tumors with an annual incidence of 1 in 40 million [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/2\" class=\"abstract_t\">2</a>]. The mean age at diagnosis of somatostatinomas is 50 to 55 years (range 26 to 84), with a roughly equal gender distribution [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"abstract_t\">3</a>]. Approximately 55 percent of somatostatinomas are in the pancreas, and, of these, two-thirds arise within the head of the pancreas. The remainder arises in the ampulla and periampullary region of the duodenum or rarely in the jejunum [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"abstract_t\">4</a>]. Other rare primary sites include the liver, colon, and rectum [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/3,5\" class=\"abstract_t\">3,5</a>]. Approximately 75 percent of somatostatinomas are malignant, and 70 to 92 percent present with metastatic disease [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"abstract_t\">6</a>].</p><p>Although 45 percent of somatostatinomas occur in association with multiple endocrine neoplasia (MEN)-1 syndrome, somatostatinomas are among the least common functioning pancreatic neuroendocrine tumors in patients with MEN-1 syndrome, occurring in less than 1 percent of patients [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"abstract_t\">7</a>]. Up to 10 percent of patients with neurofibromatosis I (NF-1; von Recklinghausen disease) develop somatostatinomas. NF-1-associated somatostatinomas are characteristically duodenal, are rarely associated with somatostatinoma syndrome, and are less likely to metastasize as compared with sporadic somatostatinomas [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/4,8\" class=\"abstract_t\">4,8</a>].</p><p class=\"headingAnchor\" id=\"H1837027389\"><span class=\"h1\">PATHOPHYSIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatin is a tetradecapeptide that normally acts in a paracrine manner to inhibit secretion of many hormones, including insulin, glucagon, gastrin, and growth hormone. It also has direct effects on a number of gastrointestinal functions [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/9\" class=\"abstract_t\">9</a>]. In patients with somatostatinomas, cholelithiasis may result from inhibition of cholecystokinin release, which reduces gallbladder contractility [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"abstract_t\">10</a>]. Diarrhea and steatorrhea result from inhibition of pancreatic enzyme and bicarbonate secretion and intestinal absorption of lipids. Many patients with somatostatinomas also have gastric hypochlorhydria due to decreased gastrin secretion. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> below and <a href=\"topic.htm?path=physiology-of-somatostatin-and-its-analogues\" class=\"medical medical_review\">&quot;Physiology of somatostatin and its analogues&quot;</a>.)</p><p>Some somatostatinomas, particularly those arising in the ampullary and periampullary area, contain immunoreactive granules but are not associated with any functional syndrome [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/8,11\" class=\"abstract_t\">8,11</a>]. In contrast, those arising in the pancreas may secrete large amounts of somatostatin, resulting in a constellation of symptoms of somatostatinoma syndrome. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> below.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common symptoms in patients with somatostatinomas, regardless of their location, are abdominal pain and weight loss.</p><p>Less often, patients present with somatostatinoma syndrome, characterized by diabetes mellitus or glucose intolerance, cholelithiasis, and <span class=\"nowrap\">diarrhea/steatorrhea</span>. Somatostatinoma syndrome is more common in patients with pancreatic somatostatinomas as compared with duodenal somatostatinomas (19 versus 2 percent), due to differences in their secretion of somatostatin [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/4,12\" class=\"abstract_t\">4,12</a>]. (See <a href=\"#H1837027389\" class=\"local\">'Pathophysiology'</a> above.)</p><p>Duodenal somatostatinomas usually present with symptoms caused by local complications [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/8,12\" class=\"abstract_t\">8,12</a>]. These symptoms include abdominal pain, obstructive jaundice, and gastrointestinal bleeding.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatinoma syndrome should be suspected in patients with the classical triad of <span class=\"nowrap\">diabetes/glucose</span> intolerance, cholelithiasis, and <span class=\"nowrap\">diarrhea/steatorrhea</span>. In patients with somatostatinoma syndrome, the diagnosis is established by the presence of a fasting plasma somatostatin level exceeding 30 <span class=\"nowrap\">pg/mL</span>. However, somatostatinoma syndrome is rare, and most somatostatinomas are detected as pancreatic or duodenal masses during the course of evaluation of abdominal pain, jaundice, or weight loss. In such patients, the diagnosis is often established by histopathology of the surgical specimen that demonstrates well-differentiated islet cells that stain positive for somatostatin on immunohistochemistry. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer#H2362725\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer&quot;, section on 'Biopsy and establishing the diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H390421\"><span class=\"h1\">TUMOR LOCALIZATION</span></p><p class=\"headingAnchor\" id=\"H1837026620\"><span class=\"h2\">Approach to imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Imaging can localize the tumor and stage the extent of disease. We begin with helical (spiral) multiphasic contrast-enhanced computed tomography (CT) for evaluation of patients with a somatostatinoma. We perform magnetic resonance imaging (MRI) when CT shows indeterminate lesions that need further characterization. In patients with inconclusive cross-sectional imaging, we perform endoscopic ultrasound (EUS). We perform somatostatin receptor scintigraphy or Gallium-68-DOTA-D-Phe1-Tyr3-Octreotate (<a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a> <span class=\"nowrap\">PET/CT)</span> if the finding of extra-abdominal metastases would change treatment. Because of its greater sensitivity, 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> is preferred over conventional somatostatin receptor scintigraphy, where available [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/13,14\" class=\"abstract_t\">13,14</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145107\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Computed tomography'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Computed tomography</strong> &ndash; Since the primary tumor is usually large (&gt;3 cm diameter) by the time of diagnosis, it is localizable by CT in the majority of cases. Intravenous contrast enhances the detection of smaller lesions, especially when images are obtained during the arterial phase. In addition, arterial phase and portal venous phase sequences can be used to maximize the conspicuity of liver metastases compared with the surrounding normal liver parenchyma.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Magnetic resonance imaging</strong> &ndash; On MRI, pancreatic neuroendocrine tumors are typically characterized by low signal intensity on T1-weighted images and high signal intensity on T2-weighted images (<a href=\"image.htm?imageKey=ONC%2F59487\" class=\"graphic graphic_diagnosticimage graphicRef59487 \">image 1</a> and <a href=\"image.htm?imageKey=ONC%2F72303\" class=\"graphic graphic_diagnosticimage graphicRef72303 \">image 2</a>). MRI may have a higher sensitivity for liver metastases as compared with CT [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145107\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Computed tomography'</a> and <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145114\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Magnetic resonance imaging'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Endoscopic ultrasound</strong> &ndash; EUS can detect pancreatic tumors as small as 2 to 3 mm, provides accurate information on the local extent of disease, and allows transmucosal needle biopsy of pancreatic lesions in patients with locally advanced tumors. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145121\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Endoscopic ultrasonography'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Somatostatin receptor scintigraphy</strong> &ndash; Somatostatin receptor scintigraphy (OctreoScan) using radiolabeled form of the somatostatin analog <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> (Indium-111 [111-In] pentetreotide) has the advantage of instantaneous whole body scanning, which also allows detection of metastases outside of the abdominal region [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/11,16\" class=\"abstract_t\">11,16</a>]. While somatostatin-receptor scintigraphy is recommended in guidelines from the European Neuroendocrine Tumor Society, the British Society of Gastroenterology, and the European Society for Medical Oncology, the <a href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp&amp;token=yAtQYciL7uywmW3eRYUeJ4aK0dRx4JGGLufx5fCsL/3GEnpty51PpRmw8L7qDt7YvrmdE8jMEGNSa6WMQQkRzhg6guWN9QugGEPeOqp3ljo=&amp;TOPIC_ID=2608\" target=\"_blank\" class=\"external\">National Comprehensive Cancer Network</a> suggests its use &quot;if appropriate&quot; [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/17-19\" class=\"abstract_t\">17-19</a>]. However, other experts have suggested that somatostatin-receptor scintigraphy be used as an adjunct for tumor staging if the finding would change patient management [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H12145128\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Indium-111 pentetreotide (OctreoScan)'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Functional PET imaging techniques</strong> &ndash; Several positron emission tomography (PET) tracers for functional imaging have emerged: 18-F-dihydroxy-phenyl-alanine (18F-DOPA), 11-C-5-hydroxytryptophan (11-C-5-HTP), 68-Ga-DOTA-D-Phe<sup>1</sup>-Tyr<sup>3</sup>-Octreotide (68-Ga-DOTATOC), and 68-Ga-DOTA-D-Phe<sup>1</sup>-Tyr<sup>3</sup>-Octreotate (68-Ga-DOTATATE). A kit for preparation of 68-Ga DOTATATE injection as a radioactive diagnostic agent for PET imaging was approved by the United States Food and Drug Administration in June 2016 for adult and pediatric patients with somatostatin receptor positive neuroendocrine tumors [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/20\" class=\"abstract_t\">20</a>]. These novel PET modalities offer higher spatial resolution than conventional somatostatin receptor scintigraphy and are associated with improved sensitivity for detection of small lesions. (See <a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring#H5\" class=\"medical medical_review\">&quot;Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring&quot;, section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The American Joint Committee on Cancer <span class=\"nowrap\">(AJCC)/Union</span> for International Cancer Control (UICC) and European Neuroendocrine Tumor Society (ENETS) have proposed the staging systems for neuroendocrine tumors (<a href=\"image.htm?imageKey=ONC%2F86409\" class=\"graphic graphic_table graphicRef86409 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"abstract_t\">21</a>]. The <span class=\"nowrap\">AJCC/UICC</span> tumor, node, metastasis (TNM) staging system covers both pancreatic exocrine and neuroendocrine malignancies. Both staging systems are highly prognostic for both relapse-free and overall survival [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/22-24\" class=\"abstract_t\">22-24</a>]. The newest release of the TNM staging classification (eight edition, 2017) has a staging system for neuroendocrine tumors of the pancreas (<a href=\"image.htm?imageKey=ONC%2F111355\" class=\"graphic graphic_table graphicRef111355 \">table 2</a>) that is separate from that used for exocrine pancreatic tumors [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms#H26599949\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;, section on 'Staging system'</a>.)</p><p class=\"headingAnchor\" id=\"H2268200622\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of somatostatinoma varies based on the clinical presentation. Somatostatinoma can be differentiated from other pancreatic and small intestine tumors by somatostatin levels and by histology.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of a pancreatic mass includes primary exocrine pancreatic cancer, other pancreatic neuroendocrine tumors, lymphoma, metastatic cancer, focal chronic pancreatitis, and autoimmune pancreatitis. Evaluation of a patient with a pancreatic mass is presented in detail separately. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer#H158747219\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer&quot;, section on 'Pancreatic mass seen on an imaging study'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of steatorrhea include cirrhosis, chronic cholestasis, bacterial overgrowth, ileal resection, or ileal disease. The evaluation of chronic diarrhea and steatorrhea are discussed in detail separately. (See <a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings#H24\" class=\"medical medical_review\">&quot;Approach to the adult with chronic diarrhea in resource-rich settings&quot;, section on 'Fatty diarrhea'</a> and <a href=\"topic.htm?path=mechanisms-of-nutrient-absorption-and-malabsorption#H2\" class=\"medical medical_review\">&quot;Mechanisms of nutrient absorption and malabsorption&quot;, section on 'Fat absorption'</a> and <a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption#H8\" class=\"medical medical_review\">&quot;Clinical features and diagnosis of malabsorption&quot;, section on 'Tests for fat malabsorption'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Pancreatic resection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Surgical resection is the treatment of choice [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/10\" class=\"abstract_t\">10</a>]. Most somatostatinomas are solitary and located in the head of the pancreas or duodenum and can be managed with pancreaticoduodenectomy. However, as 70 to 92 percent of patients present with metastatic disease, curative surgery is often not possible [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/6,26\" class=\"abstract_t\">6,26</a>]. (See <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;</a> and <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors#H185180803\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;, section on 'Others'</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Treatment of advanced/metastatic disease</span></p><p class=\"headingAnchor\" id=\"H23750494\"><span class=\"h3\">Somatostatin analogue</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Somatostatin and its analogues (eg, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a>, <a href=\"topic.htm?path=lanreotide-drug-information\" class=\"drug drug_general\">lanreotide</a>) inhibit the secretion of somatostatin and are first-line therapy for symptomatic disease in patients with unresectable tumors. Although somatostatin analogues are highly effective at controlling the symptoms of hormone hypersecretion, objective evidence of antitumor activity has not been clearly demonstrated in somatostatinomas. Control of tumor growth has been documented in metastatic midgut neuroendocrine tumors (octreotide) and gastroenteropancreatic neuroendocrine tumors without hormone-mediated symptoms (lanreotide) [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/27,28\" class=\"abstract_t\">27,28</a>]. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90693975\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Somatostatin analogs'</a>.)</p><p class=\"headingAnchor\" id=\"H23750312\"><span class=\"h3\">Liver-directed therapy for metastatic disease</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgery</strong> &ndash; Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, symptoms of hormone hypersecretion are effectively palliated and may prolong survival given the slow-growing nature of these tumors [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"abstract_t\">29</a>]. (See <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;</a> and <a href=\"topic.htm?path=overview-of-hepatic-resection\" class=\"medical medical_review\">&quot;Overview of hepatic resection&quot;</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691406\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Surgical resection'</a>.)</p><p/><p class=\"bulletIndent1\">Postoperative complications include rebound gastric acid hypersecretion and intravascular fluid overload resulting from a shift of copious amounts of fluid from the intestinal lumen. Proton pump inhibitors and <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a> are recommended in the preoperative and perioperative period to prevent these complications [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/30,31\" class=\"abstract_t\">30,31</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hepatic artery embolization and chemoembolization</strong> &ndash; Hepatic arterial embolization, with or without selective hepatic artery infusion of chemotherapy, is a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Embolization can be performed via the infusion of Gelfoam powder into the hepatic artery through an angiography catheter (bland embolization) or in conjunction with chemotherapy (ie, <a href=\"topic.htm?path=doxorubicin-conventional-drug-information\" class=\"drug drug_general\">doxorubicin</a>, <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, or <a href=\"topic.htm?path=streptozocin-drug-information\" class=\"drug drug_general\">streptozocin</a>, or drug-eluting beads) administered via the hepatic artery (chemoembolization). A third embolization technique uses radioactive isotopes (eg, yttrium-90 [90-Y]) that are tagged to glass or resin microspheres and delivered selectively to the tumor via the hepatic artery. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/32-47\" class=\"abstract_t\">32-47</a>]. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H691449\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Hepatic artery embolization'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Radiofrequency ablation and cryoablation</strong> &ndash; Ablation can be used as a primary treatment modality for neuroendocrine liver metastases or as an adjunct to surgical resection [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"abstract_t\">48</a>]. Ablation can be performed percutaneously or laparoscopically and is less invasive than either hepatic resection or hepatic artery embolization. However, ablation is applicable only to smaller lesions (typically &lt;3 cm), and its long-term efficacy is uncertain [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"abstract_t\">48</a>]. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H178294546\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Ablation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Liver transplantation</strong> &ndash; Liver transplantation is considered an investigational approach for metastatic pancreatic neuroendocrine tumors, as the number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation has been attempted is small, and follow-up data are insufficient to judge whether a complete cure has truly been achieved. (See <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H178295652\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Liver transplantation'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1922547266\"><span class=\"h3\">Molecularly targeted therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Molecularly targeted agents (eg, <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>) have a role in the management of patients with progressive advanced somatostatinomas. These and other novel therapies, such as peptide receptor radioligand therapy with radiolabeled somatostatin analogs, are discussed in detail elsewhere. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694077\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Molecularly targeted therapy'</a> and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H90694156\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Peptide receptor radioligand therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H8950844\"><span class=\"h3\">Cytotoxic chemotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who are highly symptomatic due to tumor bulk or who have rapidly enlarging metastases, chemotherapy has been used as initial treatment together with a somatostatin analogue. However, experience with systemic chemotherapy in patients with somatostatinomas is limited, and few patients have been included in chemotherapy series. The use of cytotoxic chemotherapy in patients with pancreatic neuroendocrine tumors is discussed in detail elsewhere. (See <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion#H199296649\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;, section on 'Cytotoxic chemotherapy'</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prognosis of somatostatinomas with any therapy is poor when patients present with metastatic disease [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"abstract_t\">26</a>]. There are not enough survival data on somatostatinoma to give accurate estimates of survival [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/4,49,50\" class=\"abstract_t\">4,49,50</a>]. However, 5- and 10-year survival rates for patients undergoing resection for a gastroenteropancreatic neuroendocrine tumor (both pancreatic neuroendocrine and carcinoid tumors) stratified by stage at presentation are presented in the Table (<a href=\"image.htm?imageKey=ONC%2F80523\" class=\"graphic graphic_table graphicRef80523 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">POST-TREATMENT SURVEILLANCE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is limited evidence from which to make recommendations for follow-up after resection of a somatostatinoma, and guidelines are based on expert consensus [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"abstract_t\">50</a>]. Our approach for follow-up after treatment of a somatostatinoma is consistent with guidelines from the National Comprehensive Cancer Network and consists of the following [<a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/52\" class=\"abstract_t\">52</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Three to 12 months post-resection &ndash; History and physical examination, fasting plasma somatostatin level, and computed tomography or magnetic resonance imaging.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;1 year post-resection to a maximum of 10 years &ndash; History and physical examination with fasting plasma somatostatin level every 6 to 12 months. Imaging studies as clinically indicated.</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Somatostatinomas are rare neuroendocrine tumors of D-cell origin that contain and sometimes secrete excessive amounts of somatostatin (<a href=\"image.htm?imageKey=ENDO%2F80502\" class=\"graphic graphic_figure graphicRef80502 \">figure 1</a>). The mean age at diagnosis of somatostatinomas is 50 to 55 years. Approximately 55 percent of somatostatinomas are in the pancreas, and, of these, two-thirds arise within the head of the pancreas. The remainder arises in the ampullary and periampullary area of the duodenum and rarely in the jejunum. (See <a href=\"#H1837026420\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with somatostatinomas, cholelithiasis may result from inhibition of cholecystokinin release, which reduces gallbladder contractility. Diminished insulin secretion leads to glucose <span class=\"nowrap\">intolerance/diabetes</span>. Inhibition of pancreatic enzyme and bicarbonate secretion and intestinal absorption of lipids causes diarrhea and steatorrhea. (See <a href=\"#H1837027389\" class=\"local\">'Pathophysiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common symptoms in patients with somatostatinomas, regardless of their location, are abdominal pain and weight loss. Less often, patients present with somatostatinoma syndrome characterized by diabetes <span class=\"nowrap\">mellitus/glucose</span> intolerance, cholelithiasis, and <span class=\"nowrap\">diarrhea/steatorrhea</span>. Somatostatinoma syndrome is more common in patients with pancreatic somatostatinomas as compared with duodenal somatostatinomas (19 versus 2 percent). Duodenal somatostatinomas usually present with obstructive jaundice, weight loss, and gastrointestinal bleeding. (See <a href=\"#H2\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Somatostatinoma syndrome should be suspected in patients with the classical triad of <span class=\"nowrap\">diabetes/glucose</span> intolerance, cholelithiasis, and <span class=\"nowrap\">diarrhea/steatorrhea</span>. In patients with somatostatinoma syndrome, the diagnosis is established by the presence of a fasting plasma somatostatin level exceeding 30 <span class=\"nowrap\">pg/mL</span>. However, somatostatinoma syndrome is rare, and most somatostatinomas are detected as pancreatic or duodenal masses during the course of evaluation of abdominal pain, jaundice, or weight loss. In such patients, the diagnosis is often established by histopathology of the surgical specimen that demonstrates well-differentiated islet cells that stain positive for somatostatin on immunohistochemistry. (See <a href=\"#H3\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cross-sectional imaging with multiphasic computed tomography (CT) or magnetic resonance imaging (MRI) of the abdomen can localize the tumor and stage the extent of disease. We begin with helical (spiral) multiphasic contrast-enhanced CT for evaluation of patients with a somatostatinoma. We perform MRI when CT shows indeterminate lesions that need further characterization. In patients with inconclusive cross-sectional imaging, we perform endoscopic ultrasound (EUS). We perform somatostatin receptor scintigraphy or 68-Ga-DOTA-D-Phe<sup>1</sup>-Tyr<sup>3</sup>-Octreotate (<a href=\"topic.htm?path=gallium-ga-68-dotatate-drug-information\" class=\"drug drug_general\">Gallium Ga-68 DOTATATE</a>) <span class=\"nowrap\">PET/CT</span> if the finding of extra-abdominal metastases would change treatment. Because of its greater sensitivity, 68-Ga DOTATATE <span class=\"nowrap\">PET/CT</span> may be preferable to conventional somatostatin receptor scintigraphy, where available. (See <a href=\"#H390421\" class=\"local\">'Tumor localization'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>As with other neuroendocrine tumors, surgical resection is the treatment of choice. However, because 75 percent of patients have tumors that have metastasized by the time the diagnosis is made, curative surgery is often not possible. (See <a href=\"#H6\" class=\"local\">'Pancreatic resection'</a> above and <a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors#H185180803\" class=\"medical medical_review\">&quot;Surgical resection of sporadic pancreatic neuroendocrine tumors&quot;, section on 'Others'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatic resection can be considered in patients with metastatic disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases. Hepatic arterial embolization, with or without selective hepatic artery infusion of chemotherapy, may be used for palliation in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Long-term efficacy of radiofrequency ablation and cryoablation are unknown, and experience with orthotopic liver transplantation is limited. Benefit has been shown for cytotoxic chemotherapy and molecularly targeted agents such as <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a> and <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>. (See <a href=\"#H8\" class=\"local\">'Treatment of advanced/metastatic disease'</a> above and <a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion&quot;</a> and <a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">&quot;Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prognosis is generally poor when patients present with metastatic disease. Our approach for follow-up after treatment of a somatostatinoma is consistent with guidelines from the National Comprehensive Cancer Network and consists of the following (see <a href=\"#H13\" class=\"local\">'Prognosis'</a> above and <a href=\"#H14\" class=\"local\">'Post-treatment surveillance'</a> above):</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Three to 12 months post-resection &ndash; History and physical examination, fasting plasma somatostatin level, and computed tomography or magnetic resonance imaging.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>&gt;1 year post-resection to a maximum of 10 years &ndash; History and physical examination with fasting plasma somatostatin level every 6 to 12 months. Imaging studies as clinically indicated.</p><p/><p class=\"headingAnchor\" id=\"H1914050996\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The UpToDate editorial staff would like to thank Dr. Stephen E. Goldfinger, MD, for his past contributions as an author to this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/1\" class=\"nounderline abstract_t\">Friesen SR. Update on the diagnosis and treatment of rare neuroendocrine tumors. Surg Clin North Am 1987; 67:379.</a></li><li class=\"breakAll\">Jensen RT, Norton JA. Endocrine tumors of the pancreas. In: Sleisenger &amp; Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders, Philadelphia 2002. p.988.</li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/3\" class=\"nounderline abstract_t\">Harris GJ, Tio F, Cruz AB Jr. Somatostatinoma: a case report and review of the literature. J Surg Oncol 1987; 36:8.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/4\" class=\"nounderline abstract_t\">Soga J, Yakuwa Y. Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999; 18:13.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/5\" class=\"nounderline abstract_t\">Ohwada S, Joshita T, Ishihara T, et al. Primary liver somatostatinoma. J Gastroenterol Hepatol 2003; 18:1218.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/6\" class=\"nounderline abstract_t\">Doherty GM. Rare endocrine tumours of the GI tract. Best Pract Res Clin Gastroenterol 2005; 19:807.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/7\" class=\"nounderline abstract_t\">Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer 2008; 15:229.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/8\" class=\"nounderline abstract_t\">Mao C, Shah A, Hanson DJ, Howard JM. Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas. J Surg Oncol 1995; 59:67.</a></li><li class=\"breakAll\">Jensen RT, Norton JA. Endocrine neoplasms of the pancreas. In: Textbook of Gastroenterology, Yamada T (Ed), JB Lippincott Co, Philadelphia 1995. p.2131.</li><li class=\"breakAll\">Snow ND, Liddle RA. Neuroendocrine Tumors. In: Gastrointestinal Cancers: Biology, Diagnosis and Therapy, Rustgi AK (Ed), Lippincott-Raven, Philadelphia 1995. p.585.</li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/11\" class=\"nounderline abstract_t\">Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998; 42:792.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/12\" class=\"nounderline abstract_t\">O'Brien TD, Chejfec G, Prinz RA. Clinical features of duodenal somatostatinomas. Surgery 1993; 114:1144.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/13\" class=\"nounderline abstract_t\">Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/14\" class=\"nounderline abstract_t\">Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/15\" class=\"nounderline abstract_t\">Reidy-Lagunes DL, Gollub MJ, Saltz LB. Addition of octreotide functional imaging to cross-sectional computed tomography or magnetic resonance imaging for the detection of neuroendocrine tumors: added value or an anachronism? J Clin Oncol 2011; 29:e74.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/16\" class=\"nounderline abstract_t\">Nikou GC, Toubanakis C, Nikolaou P, et al. VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 2005; 52:1259.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/17\" class=\"nounderline abstract_t\">Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95:120.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/18\" class=\"nounderline abstract_t\">Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/19\" class=\"nounderline abstract_t\">&Ouml;berg K, Knigge U, Kwekkeboom D, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii124.</a></li><li class=\"breakAll\">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524 (Accessed on June 08, 2016).</li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/21\" class=\"nounderline abstract_t\">Rindi G, Kl&ouml;ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/22\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/23\" class=\"nounderline abstract_t\">Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/24\" class=\"nounderline abstract_t\">Cho JH, Ryu JK, Song SY, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016; 45:941.</a></li><li class=\"breakAll\">Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), AJCC, Chicago 2017. p.407.</li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/26\" class=\"nounderline abstract_t\">House MG, Yeo CJ, Schulick RD. Periampullary pancreatic somatostatinoma. Ann Surg Oncol 2002; 9:869.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/27\" class=\"nounderline abstract_t\">Caplin ME, Pavel M, &#262;wik&#322;a JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014; 371:224.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/28\" class=\"nounderline abstract_t\">Rinke A, Wittenberg M, Schade-Brittinger C, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival. Neuroendocrinology 2017; 104:26.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/29\" class=\"nounderline abstract_t\">Anene C, Thompson JS, Saigh J, et al. Somatostatinoma: atypical presentation of a rare pancreatic tumor. Am J Gastroenterol 1995; 90:819.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/30\" class=\"nounderline abstract_t\">Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993; 32:203.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/31\" class=\"nounderline abstract_t\">O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989; 18:545.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/32\" class=\"nounderline abstract_t\">Sw&auml;rd C, Johanson V, Nieveen van Dijkum E, et al. Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 2009; 96:517.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/33\" class=\"nounderline abstract_t\">Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 1993; 71:2624.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/34\" class=\"nounderline abstract_t\">Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998; 83:2293.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/35\" class=\"nounderline abstract_t\">Christante D, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. Surgery 2008; 144:885.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/36\" class=\"nounderline abstract_t\">Drougas JG, Anthony LB, Blair TK, et al. Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors. Am J Surg 1998; 175:408.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/37\" class=\"nounderline abstract_t\">Loewe C, Schindl M, Cejna M, et al. Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. AJR Am J Roentgenol 2003; 180:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/38\" class=\"nounderline abstract_t\">de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008; 19:855.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/39\" class=\"nounderline abstract_t\">Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31:271.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/40\" class=\"nounderline abstract_t\">Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008; 247:1029.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/41\" class=\"nounderline abstract_t\">King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113:921.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/42\" class=\"nounderline abstract_t\">Gaur SK, Friese JL, Sadow CA, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol 2011; 34:566.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/43\" class=\"nounderline abstract_t\">Arrese D, McNally ME, Chokshi R, et al. Extrahepatic disease should not preclude transarterial chemoembolization for metastatic neuroendocrine carcinoma. Ann Surg Oncol 2013; 20:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/44\" class=\"nounderline abstract_t\">Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104:1590.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/45\" class=\"nounderline abstract_t\">Cao CQ, Yan TD, Bester L, et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97:537.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/46\" class=\"nounderline abstract_t\">Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83:887.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/47\" class=\"nounderline abstract_t\">Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 2003; 9:261.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/48\" class=\"nounderline abstract_t\">Moug SJ, Leen E, Horgan PG, Imrie CW. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma. Pancreatology 2006; 6:155.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/49\" class=\"nounderline abstract_t\">Hamy A, Heymann MF, Bodic J, et al. [Duodenal somatostatinoma. Anatomic/clinical study of 12 operated cases]. Ann Chir 2001; 126:221.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/50\" class=\"nounderline abstract_t\">Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735.</a></li><li><a href=\"https://www.uptodate.com/contents/somatostatinoma-clinical-manifestations-diagnosis-and-management/abstract/51\" class=\"nounderline abstract_t\">Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.</a></li><li class=\"breakAll\">National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).</li></ol></div><div id=\"topicVersionRevision\">Topic 2608 Version 22.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H15\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H1837026420\" id=\"outline-link-H1837026420\">EPIDEMIOLOGY</a></li><li><a href=\"#H1837027389\" id=\"outline-link-H1837027389\">PATHOPHYSIOLOGY</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">DIAGNOSIS</a></li><li><a href=\"#H390421\" id=\"outline-link-H390421\">TUMOR LOCALIZATION</a><ul><li><a href=\"#H1837026620\" id=\"outline-link-H1837026620\">Approach to imaging</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">STAGING</a></li><li><a href=\"#H2268200622\" id=\"outline-link-H2268200622\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">TREATMENT</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Pancreatic resection</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Treatment of advanced/metastatic disease</a><ul><li><a href=\"#H23750494\" id=\"outline-link-H23750494\">- Somatostatin analogue</a></li><li><a href=\"#H23750312\" id=\"outline-link-H23750312\">- Liver-directed therapy for metastatic disease</a></li><li><a href=\"#H1922547266\" id=\"outline-link-H1922547266\">- Molecularly targeted therapy</a></li><li><a href=\"#H8950844\" id=\"outline-link-H8950844\">- Cytotoxic chemotherapy</a></li></ul></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">PROGNOSIS</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">POST-TREATMENT SURVEILLANCE</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">SUMMARY</a></li><li><a href=\"#H1914050996\" id=\"outline-link-H1914050996\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/2608|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/59487\" class=\"graphic graphic_diagnosticimage\">- MRI pancreatic neuroendocrine tumor</a></li><li><a href=\"image.htm?imageKey=ONC/72303\" class=\"graphic graphic_diagnosticimage\">- MRI well differentiated pancreatic neuroendocrine tumor</a></li></ul></li><li><div id=\"GAST/2608|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/80502\" class=\"graphic graphic_figure\">- Islets of Langerhans</a></li></ul></li><li><div id=\"GAST/2608|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/86409\" class=\"graphic graphic_table\">- ENETS staging system for pancreatic NETS</a></li><li><a href=\"image.htm?imageKey=ONC/111355\" class=\"graphic graphic_table\">- Neuroendocrine tumors of the pancreas TNM 2017</a></li><li><a href=\"image.htm?imageKey=ONC/80523\" class=\"graphic graphic_table\">- Survival rates following resection of a pancreatic NET</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-chronic-diarrhea-in-resource-rich-settings\" class=\"medical medical_review\">Approach to the adult with chronic diarrhea in resource-rich settings</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-and-diagnosis-of-malabsorption\" class=\"medical medical_review\">Clinical features and diagnosis of malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-staging-of-exocrine-pancreatic-cancer\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=glucagonoma-and-the-glucagonoma-syndrome\" class=\"medical medical_review\">Glucagonoma and the glucagonoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">Insulinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-prognosis-of-the-zollinger-ellison-syndrome-gastrinoma\" class=\"medical medical_review\">Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanisms-of-nutrient-absorption-and-malabsorption\" class=\"medical medical_review\">Mechanisms of nutrient absorption and malabsorption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-gastroenteropancreatic-neuroendocrine-tumors-presentation-prognosis-imaging-and-biochemical-monitoring\" class=\"medical medical_review\">Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metastatic-well-differentiated-pancreatic-neuroendocrine-tumors-systemic-therapy-options-to-control-tumor-growth-and-symptoms-of-hormone-hypersecretion\" class=\"medical medical_review\">Metastatic well-differentiated pancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hepatic-resection\" class=\"medical medical_review\">Overview of hepatic resection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=physiology-of-somatostatin-and-its-analogues\" class=\"medical medical_review\">Physiology of somatostatin and its analogues</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=surgical-resection-of-sporadic-pancreatic-neuroendocrine-tumors\" class=\"medical medical_review\">Surgical resection of sporadic pancreatic neuroendocrine tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vipoma-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">VIPoma: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=zollinger-ellison-syndrome-gastrinoma-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis</a></li></ul></div></div>","javascript":null}